Latest Headlines
-
Introducing CPC Biotech—One Brand Uniting Critical Fluid Management Components
4/17/2026
CPC Biotech to make its public debut at INTERPHEX 2026, April 21–23, Javits Center, New York City.
- AST And Marchesini Group Debut Partnership Benefit With Expanded Drug Product Manufacturing Portfolio At INTERPHEX 2026 4/14/2026
-
Grand River Aseptic Manufacturing Announces $100 Million Investment In Sterile Manufacturing Capabilities
4/14/2026
Grand River Aseptic Manufacturing (“GRAM”), an Arlington Capital Partners portfolio company, is a leading provider of sterile fill-finish services. The company has announced a significant investment to expand its sterile injectable drug product manufacturing capacity and capabilities for high-volume commercial products.
- Ensorcell Launches Versaweldâ„¢ Precision Tube Welding Platform At INTERPHEX 2026 4/10/2026
- Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 With Selection Of Cytovance Biologics For Cgmp Manufacturing 4/10/2026
-
Symbiosis Expands Commercial Capabilities With Addition Of New Stability Chamber
4/1/2026
Symbiosis Pharmaceutical Services (Symbiosis), a Contract Development and Manufacturing Organisation (CDMO) specialising in the sterile GMP manufacturer of injectable drug products, has expanded its Quality Control (QC) laboratory with the installation of a new 30°C stability chamber.
-
Samsung Biologics Completes Acquisition Of GSK's Manufacturing Facility In Rockville, Maryland
3/31/2026
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States.
- Gore Expands Leadership In Membrane Chromatography With Next-Generation Affinity Solutions 3/31/2026
-
Lonza Launches Media Development Lab In Singapore For Cell Culture Media Optimization
3/26/2026
Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of its Media Development Lab at its Singapore site.
-
UCB Announces New Biologics Manufacturing Facility Investment In Georgia
3/25/2026
The State of Georgia, Gwinnett County and the Rowen Foundation today announced that global biopharmaceutical company UCB has selected Rowen as the site of its new U.S. biologics manufacturing campus. The planned project represents a direct investment of approximately $2 billion and is expected to create more than 330 high-quality jobs as the facility comes online over the next several years.